Cartesian Therapeutics Stock Gains on Full-Year Revenue Beat

Dow Jones

03/10

By Elias Schisgall

Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year.

Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year.

The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier.

Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000.

Analysts were expecting a loss of $2.35 a share and $2 million in revenue.

The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness.

It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 09, 2026 13:51 ET (17:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2618675097"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618675097\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618675097?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 01:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618675097","market":"sg","top_or_hot":-1,"title":"Cartesian Therapeutics Stock Gains on Full-Year Revenue Beat","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. \n</p>\n<p>\n  Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year. \n</p>\n<p>\n  The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier. \n</p>\n<p>\n  Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000. \n</p>\n<p>\n  Analysts were expecting a loss of $2.35 a share and $2 million in revenue. \n</p>\n<p>\n  The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness. \n</p>\n<p>\n  It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cartesian Therapeutics Stock Gains on Full-Year Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCartesian Therapeutics Stock Gains on Full-Year Revenue Beat\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-10 01:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. \n</p>\n<p>\n  Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year. \n</p>\n<p>\n  The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier. \n</p>\n<p>\n  Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000. \n</p>\n<p>\n  Analysts were expecting a loss of $2.35 a share and $2 million in revenue. \n</p>\n<p>\n  The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness. \n</p>\n<p>\n  It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNAC","symbol_name":"Cartesian Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618675097","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618675097","pubTimestamp":1773078660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year.Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year.The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier.Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000.Analysts were expecting a loss of $2.35 a share and $2 million in revenue.The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness.It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation,","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RNAC":"Cartesian Therapeutics"},"translate_title":"Cartesian Therapeutics股价因全年收入超出预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAC":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. \n\n\n  Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year. \n\n\n  The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier. \n\n\n  Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000. \n\n\n  Analysts were expecting a loss of $2.35 a share and $2 million in revenue. \n\n\n  The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness. \n\n\n  It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 13:51 ET (17:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}